Background: The fractional concentration of exhaled nitric oxide (FeNO) is a surrogate biomarker for Th2-dependent bronchial inflammation. The present study investigated whether FeNO may characterize allergic rhinitis (AR) patients. Methods: A total of 553 AR patients (497 males, mean age 28.8 years) were evaluated. Those patients with a high FeNO underwent a 2-year follow-up. Results: Increased FeNO was associated with a significantly longer AR duration, impaired lung function, more severe symptoms, and more frequent bronchial hyperresponsiveness (BHR). At follow-up, 22 out of 82 patients (26.8%) with high FeNO levels (>50 ppb) developed asthma. Conclusions: AR patients may frequently have high FeNO values, exceeding 50 ppb. This might be associated with an initial impaired lung function, BHR, a perceived worsening of respiratory symptoms, and potential progression to asthma.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(suppl 86):8-160.
Corren J: The connection between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med 2007;13:13-18.
König K, Klemens C, Eder K, San Nicoló M, Becker S, Kramer MF, Gröger M: Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis. Allergy Asthma Clin Immunol 2015;11:26.
Global Initiative for Asthma: GINA guidelines: global strategy for asthma management and prevention. htpp:// (accessed October 2016).
Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al: American Thoracic Society Committee on interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-615.
Lee J, Lim KT: Growth of HepG2 cells was suppressed through modulation of STAT6/IL-4 and IL-10 in RAW 264.7 cells treated by phytoglycoprotein (38 kDa). Inflammation 2013;36:549-560.
Leung TF, Ko FW, Wong GW: Recent advances in asthma biomarker research. Ther Adv Respir Dis 2013;7:297-308.
Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG: Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther 2015;53:1015-1027.
Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, et al: The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014;44:38-46.
Ricciardolo FLM: Revisiting the role exhaled nitric oxide in asthma. Curr Opin Pulm Med 2014;20:53-59.
Ciprandi G, Signori A, Tosca MA, Cirillo I: Spirometric abnormalities in patients with allergic rhinitis: indicator of an asthma march? Am J Rhinol Allergy 2011;32:22-28.
Ciprandi G, Cirillo I: FEF25-75 may be a marker of bronchial impairment in allergic rhinitis. J Allergy Clin Immunol 2011;127:549-551.
Di Cara G, Marcucci F, Palomba A, Milioni M, Pecoraro L, Ciprandi G, et al: Exhaled nitric oxide in children with allergic rhinitis: a potential biomarker of asthma development. Pediatr Allergy Immunol 2015;26:85-87.
Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, Bousquet J: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007;62:367-372.
Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, Bousquet PJ, Burney PG, et al: Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2012;67:18-24.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al: Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-968.
Miller MR, Hankinson J, Brusasco V, Burgos R, Casaburi R, Coates R, et al: Standardisation of spirometry. Eur Respir J 2005;26:319-338.
Crapo RO, Casaburi R, Coates AL, et al: Guidelines for methacholine and exercise challenge testing - 1999. Am J Resp Crit Care Med 2000;161:309-329.
R Core Team: R: a language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2016.
Ciprandi G, Cirillo I, Pistorio A: Impact of allergic rhinitis on asthma: effects on spirometric parameters. Allergy 2008;63:255-260.
Cirillo I, Pistorio A, Tosca MA, Ciprandi G: Impact of allergic rhinitis on asthma: effects on bronchial hyperreactivity. Allergy 2009;64:439-444.
Camargos P, Ibiapina C, Lasmar L, Cruz AA: Obtaining concomitant control of allergic rhinitis and asthma with a nasally inhaled corticosteroid. Allergy 2007;62:310-316.
Price D, Kemp L, Sims E, von Ziegenweidt J, Navaratnam P, Lee AJ, Chisholm A, Hillyer EV, Gopalan G: Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J 2010;19:266-273.
Berger WE, Schenkel EJ, Mansfield LE; Desloratadine Study Group: Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485-491.
Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-857.
Skiepko R, Zietkowski Z, Tomasiak-Lozowska MM, Tomasiak M, Bodzenta-Lukaszyk A: Bronchial hyperresponsiveness and airway inflammation in patients with seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2011;21:532-539.
Yilmaz I, Bayraktar N, Ceyhan K, et al: Evaluation of vascular endothelial growth factor A and endostatin levels in induced sputum and relationship to bronchial hyperreactivity in patients with seasonal allergic rhinitis. Am J Rhinol Allergy 2013;27:181-186.
Cirillo I, Ricciardolo F, Medusei G, Signori A, Ciprandi G: Exhaled nitric oxide may predict bronchial hyperreactivity in patients with allergic rhinitis. Int Arch Allergy Immunol 2013;160:322-328.
Zeiger RS, Schatz M, Zhang F, Crawford WW, Kaplan MS, Roth RM, et al: Association of exhaled nitric oxide to asthma burden in asthmatics on inhaled corticosteroids. J Asthma 2011;48:8-17.
Ciprandi G, Ricciardolo FL, Schiavetti I, Cirillo I: Allergic rhinitis phenotypes based on bronchial hyperreactivity to methacholine. Am J Rhinol Allergy 2014;28:214-218.
Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW: A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol 2016;170:122-131.
Perzanowski MS, Yoo Y: Exhaled nitric oxide and airway hyperresponsiveness to adenosine 5′-monophosphate and methacholine in children with asthma. Int Arch Allergy Immunol 2015;166:107-113.
Muñoz X, Bustamante V, Lopez-Campos JL, Cruz MJ, Barreiro E: Usefulness of noninvasive methods for the study of bronchial inflammation in the control of patients with asthma. Int Arch Allergy Immunol 2015;166:1-12.
Lozano J, Cruz MJ, Piquer M, Giner MT, Plaza AM: Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath. Int Arch Allergy Immunol 2014;165:140-147.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.